23andMe Co-Founder Wins Auction for Genetic Data

23andMe co-founder Anne Wojcicki and the TTAM Research Institute won an auction to acquire the bankrupt genetic analysis company's assets, including a cache of customer DNA data, for $305 million. Their bid exceeded Regeneron Pharmaceuticals' offer by nearly $50 million, though Regeneron remains the backup bidder pending court approval of the sale.

Analysis

The auction for bankrupt 23andMe's assets, primarily its extensive customer DNA database, culminated in a $305 million winning bid from co-founder Anne Wojcicki and the TTAM Research Institute. This valuation, nearly $50 million above Regeneron Pharmaceuticals' (REGN) competing offer, underscores the significant perceived value of large-scale genetic datasets, even from a distressed entity. Wojcicki's involvement, alongside a non-profit research institute, suggests a potential shift in the data's application towards research-focused endeavors, distinct from its previous commercial context. Regeneron's position as the backup bidder, with a substantial offer, highlights the robust interest from major pharmaceutical companies in leveraging such data for drug discovery and development. The transaction remains subject to federal judge approval, introducing a contingent element to the outcome. This event reflects ongoing M&A activity within the biotechnology and data sectors, emphasizing the strategic importance of genetic information, while also implicitly raising considerations around data governance and a co-founder re-acquiring sensitive assets post-bankruptcy.

Key Decisions for Investors

• For Regeneron (REGN) investors, the unsuccessful primary bid for 23andMe's assets means no immediate capital deployment for this specific acquisition, which can be viewed neutrally given the complexities of integrating data from a bankrupt firm, yet the substantial offer confirms REGN's strategic pursuit of large genetic datasets.
• Investors should recognize REGN's persistent interest in leveraging genetic information for its R&D pipeline, as indicated by its aggressive bidding, and anticipate potential future endeavors by the company to secure similar data assets through other acquisitions or partnerships.
• Monitor the final court approval of the winning bid, as Regeneron remains the contingent backup acquirer, and consider this event as indicative of the high competitive value placed on unique data assets in the biopharmaceutical industry.